The European Society for Medical Oncology (ESMO) 2020 was held virtually from 19–21 September. ESMO 2020 brought together leading experts from around the globe, who presented the latest cutting-edge advancements in the field of oncology.

View all videos

ESMO 2020

European Society for Medical Oncology Congress
ESMO 2020 19th – 21st September

JUST OUT📢 @US_FDA 🇺🇸APPROVES fam-trastuzumab deruxtecan-nxki🧪for locally advanced or metastatic #HER2 ➕Gastric or gastroesophageal #Cancer w/prior trastuzumab‼️#GI21

✅OS 12.5 Vs 8.4 mo (iri/pacli)
✅ORR 40.5% Vs 11.3%
✅Median PFS 5.6 Vs 3.5 mo

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas

Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC)

163 trials:
-Females comprised 25% authorship (11% had 0 women)
-Female 1st author: 21%, Senior author: 11%
-For publications with IF>20, 13% female first, 0% senior

#GI21

Today the FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

#HER2

#GI21 @ASCO #PosterSession
#PARADIGM study of #mFOLFOX6 plus #panitumumab or #bevacizumab as #firstline treatment in patients with #RAS (KRAS/NRAS) wild-type #MetastaticColorectalCancer.

@ASCO_pubs @adbeggs @OncoUgi @nicole_anand @VJHemOnc @VJOncology @SweetNurseOnco

We spoke w/ Richard D. Kim of @MoffittNews on the ongoing Phase Ib study evaluating #regorafenib in advanced #HCC ⬇️

👉http://ow.ly/ckiA50D9uVy👈

@VJOncology @OncoAlert @ASCO #GI21 #GIsm #LiverCancer #OncoAlert

Load More

ESMO 2020

European Society for Medical Oncology Congress
ESMO 2020 19th – 21st September

The European Society for Medical Oncology (ESMO) 2020 was held virtually from 19–21 September. ESMO 2020 brought together leading experts from around the globe, who presented the latest cutting-edge advancements in the field of oncology.

View all videos

JUST OUT📢 @US_FDA 🇺🇸APPROVES fam-trastuzumab deruxtecan-nxki🧪for locally advanced or metastatic #HER2 ➕Gastric or gastroesophageal #Cancer w/prior trastuzumab‼️#GI21

✅OS 12.5 Vs 8.4 mo (iri/pacli)
✅ORR 40.5% Vs 11.3%
✅Median PFS 5.6 Vs 3.5 mo

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas

Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC)

163 trials:
-Females comprised 25% authorship (11% had 0 women)
-Female 1st author: 21%, Senior author: 11%
-For publications with IF>20, 13% female first, 0% senior

#GI21

Today the FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

#HER2

#GI21 @ASCO #PosterSession
#PARADIGM study of #mFOLFOX6 plus #panitumumab or #bevacizumab as #firstline treatment in patients with #RAS (KRAS/NRAS) wild-type #MetastaticColorectalCancer.

@ASCO_pubs @adbeggs @OncoUgi @nicole_anand @VJHemOnc @VJOncology @SweetNurseOnco

We spoke w/ Richard D. Kim of @MoffittNews on the ongoing Phase Ib study evaluating #regorafenib in advanced #HCC ⬇️

👉http://ow.ly/ckiA50D9uVy👈

@VJOncology @OncoAlert @ASCO #GI21 #GIsm #LiverCancer #OncoAlert

Load More

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter